Cargando…

2238. Evaluation of Adjuvant Interferon-Gamma-Level Assessment to Improve the Performance of Procalcitonin Testing in Hospitalized Bacteremic Patients

BACKGROUND: Although procalcitonin-guided antimicrobial stewardship has had proven utility in emergency and ICU settings, it is still not widely adopted outside these areas. One limitation to a more universal uptake has been the unreliable performance in discriminating bacterial infected from uninfe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ololade, Shafiu O, Patel, Kavya, Lafarga, Derek G, Apewokin, Senu K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809583/
http://dx.doi.org/10.1093/ofid/ofz360.1916
_version_ 1783462024365211648
author Ololade, Shafiu O
Patel, Kavya
Lafarga, Derek G
Apewokin, Senu K
author_facet Ololade, Shafiu O
Patel, Kavya
Lafarga, Derek G
Apewokin, Senu K
author_sort Ololade, Shafiu O
collection PubMed
description BACKGROUND: Although procalcitonin-guided antimicrobial stewardship has had proven utility in emergency and ICU settings, it is still not widely adopted outside these areas. One limitation to a more universal uptake has been the unreliable performance in discriminating bacterial infected from uninfected individuals. Viral infections have been noted to suppress procalcitonin (PCT) levels through Interferon-gamma (IFN-G)-mediated inhibition of procalcitonin release from parenchymal cells. Unfortunately, clinical application algorithms do not assess INF-G levels at the time evaluation thus treating providers are unable to distinguish a true-negative test from a false-negative test resulting from INF-G-mediated procalcitonin suppression This undermines the performance of PCT, particularly in patients with bacterial and viral co-infections. We hypothesized that adjuvant interferon gamma testing could improve the performance of PCT. To test this hypothesis we prospectively enrolled bacteremic hospitalized patients along with culture-negative controls and then assessed the performance of PCT with adjuvant IFN-G testing. METHODS: 69 hospitalized patients with bacteremia and 32 culture-negative controls were enrolled. Demographic and clinical parameters were compared between groups alongside INFG and PCT levels Parametric and non-parametric statistical tests were performed where appropriate. Test performance was evaluated by constructing receiver operator curves (ROCs) for PCT, INF-G, and a combination of PCT+INF-G. RESULTS: Of 101 patients enrolled, the mean age was 49.46 ± 13.6 years with 47% being female. The following were comparative statistics between the culture-positive vs. culture-negative group: mean age 52.1 ± 15.7 vs. 46.4 ± 14.2 years, P = 0.56; WBC 11.9 ± 9.5 vs. 9.5±5.1, P = 0.170; ANC 8,466 ± 5,686 vs. 8,189 ± 4,769, P = 0.907; eGFR 73.2 ± 23 vs. 74.5 ± 26.1, P = 0.644; PCT 2.79 ± 5.87 vs. 0.71 ± 1.79, P = 0.03. Of these 57 patients had INF-G and PCT values available and their corresponding ROCs are shown in figure. CONCLUSION: Our interim results indicate adjuvant INF-G testing may not improve the performance of procalcitonin in hospitalized bacteremic patients. The additional samples are being analyzed to confirm these findings. [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6809583
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68095832019-10-28 2238. Evaluation of Adjuvant Interferon-Gamma-Level Assessment to Improve the Performance of Procalcitonin Testing in Hospitalized Bacteremic Patients Ololade, Shafiu O Patel, Kavya Lafarga, Derek G Apewokin, Senu K Open Forum Infect Dis Abstracts BACKGROUND: Although procalcitonin-guided antimicrobial stewardship has had proven utility in emergency and ICU settings, it is still not widely adopted outside these areas. One limitation to a more universal uptake has been the unreliable performance in discriminating bacterial infected from uninfected individuals. Viral infections have been noted to suppress procalcitonin (PCT) levels through Interferon-gamma (IFN-G)-mediated inhibition of procalcitonin release from parenchymal cells. Unfortunately, clinical application algorithms do not assess INF-G levels at the time evaluation thus treating providers are unable to distinguish a true-negative test from a false-negative test resulting from INF-G-mediated procalcitonin suppression This undermines the performance of PCT, particularly in patients with bacterial and viral co-infections. We hypothesized that adjuvant interferon gamma testing could improve the performance of PCT. To test this hypothesis we prospectively enrolled bacteremic hospitalized patients along with culture-negative controls and then assessed the performance of PCT with adjuvant IFN-G testing. METHODS: 69 hospitalized patients with bacteremia and 32 culture-negative controls were enrolled. Demographic and clinical parameters were compared between groups alongside INFG and PCT levels Parametric and non-parametric statistical tests were performed where appropriate. Test performance was evaluated by constructing receiver operator curves (ROCs) for PCT, INF-G, and a combination of PCT+INF-G. RESULTS: Of 101 patients enrolled, the mean age was 49.46 ± 13.6 years with 47% being female. The following were comparative statistics between the culture-positive vs. culture-negative group: mean age 52.1 ± 15.7 vs. 46.4 ± 14.2 years, P = 0.56; WBC 11.9 ± 9.5 vs. 9.5±5.1, P = 0.170; ANC 8,466 ± 5,686 vs. 8,189 ± 4,769, P = 0.907; eGFR 73.2 ± 23 vs. 74.5 ± 26.1, P = 0.644; PCT 2.79 ± 5.87 vs. 0.71 ± 1.79, P = 0.03. Of these 57 patients had INF-G and PCT values available and their corresponding ROCs are shown in figure. CONCLUSION: Our interim results indicate adjuvant INF-G testing may not improve the performance of procalcitonin in hospitalized bacteremic patients. The additional samples are being analyzed to confirm these findings. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809583/ http://dx.doi.org/10.1093/ofid/ofz360.1916 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Ololade, Shafiu O
Patel, Kavya
Lafarga, Derek G
Apewokin, Senu K
2238. Evaluation of Adjuvant Interferon-Gamma-Level Assessment to Improve the Performance of Procalcitonin Testing in Hospitalized Bacteremic Patients
title 2238. Evaluation of Adjuvant Interferon-Gamma-Level Assessment to Improve the Performance of Procalcitonin Testing in Hospitalized Bacteremic Patients
title_full 2238. Evaluation of Adjuvant Interferon-Gamma-Level Assessment to Improve the Performance of Procalcitonin Testing in Hospitalized Bacteremic Patients
title_fullStr 2238. Evaluation of Adjuvant Interferon-Gamma-Level Assessment to Improve the Performance of Procalcitonin Testing in Hospitalized Bacteremic Patients
title_full_unstemmed 2238. Evaluation of Adjuvant Interferon-Gamma-Level Assessment to Improve the Performance of Procalcitonin Testing in Hospitalized Bacteremic Patients
title_short 2238. Evaluation of Adjuvant Interferon-Gamma-Level Assessment to Improve the Performance of Procalcitonin Testing in Hospitalized Bacteremic Patients
title_sort 2238. evaluation of adjuvant interferon-gamma-level assessment to improve the performance of procalcitonin testing in hospitalized bacteremic patients
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809583/
http://dx.doi.org/10.1093/ofid/ofz360.1916
work_keys_str_mv AT ololadeshafiuo 2238evaluationofadjuvantinterferongammalevelassessmenttoimprovetheperformanceofprocalcitonintestinginhospitalizedbacteremicpatients
AT patelkavya 2238evaluationofadjuvantinterferongammalevelassessmenttoimprovetheperformanceofprocalcitonintestinginhospitalizedbacteremicpatients
AT lafargaderekg 2238evaluationofadjuvantinterferongammalevelassessmenttoimprovetheperformanceofprocalcitonintestinginhospitalizedbacteremicpatients
AT apewokinsenuk 2238evaluationofadjuvantinterferongammalevelassessmenttoimprovetheperformanceofprocalcitonintestinginhospitalizedbacteremicpatients